# US 2006/0069158 A1 · Lipoxin compounds and their use in treating cell proliferative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0069158 A1
- Document ID: US20060069158A1
- Status: Published application
- Kind: A1
- Application number: 11/222,172
- Filed: 2005-09-08
- Published: 2006-03-30
- Earliest claimed: 1993-06-15
- Inventors: Charles Serhan
- Web page: https://patentgrep.com/patent/US20060069158A1

## CPC

- C07C 69/736: the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/232: having three or more double bonds, e.g. etretinate
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C07C 59/42: containing hydroxy or O-metal groups
- C07C 69/587: Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
- C07C 69/732: of unsaturated hydroxy carboxylic acids
- C07C 69/734: Ethers
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.

## Claims

### Claim 1

A method for treating a subject for restenosis comprising administering to said subject a composition comprising an effective amount of a lipoxin A4 compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that restenosis is prevented, reduced, or inhibited.

### Claim 2 (depends on 2)

The method of claim 2, wherein the lipoxin A4 compound is LXA4 or 15-R/S-methyl, LXA4.

### Claim 3

A method for treating a subject for restenosis comprising administering to said subject a composition comprising an effective amount of a 15-epi-lipoxin A4 compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that restenosis is prevented, reduced, or inhibited.

### Claim 4 (depends on 3)

The method of claim 3, wherein the 15-epi-lipoxin A4 compound is 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4.
